Survivin (BIRC5) Peptide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study

Survivin (BIRC5) Peptide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study

A triple negative breast cancer model using the murine 4T1 tumor cell line was used to explore the efficacy of an adjuvanted survivin peptide microparticle vaccine using tumor growth as the outcome metric. We first performed tumor cell dose titration studies to determine a tumor cell dose that resul...

Full description

Bibliographic Details
Main Authors: Scott R. Burkholz, Charles V. Herst, Richard T. Carback, Paul E. Harris, Reid M. Rubsamen
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Vaccines
Subjects:
breast cancer
immunotherapy
bioinformatics
next-generation sequencing
neoadjuvant therapy
tumor-associated antigen
Online Access:https://www.mdpi.com/2076-393X/11/3/644

Internet

https://www.mdpi.com/2076-393X/11/3/644

Similar Items